Zomedica Corp. (NYSEAMERICAN:ZOM – Get Rating) Director Johnny D. Powers bought 100,000 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was purchased at an average price of $0.19 per share, for a total transaction of $19,000.00. Following the acquisition, the director now directly owns 1,600,000 shares in the company, valued at $304,000. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
Zomedica Stock Performance
Shares of ZOM opened at $0.19 on Friday. Zomedica Corp. has a one year low of $0.15 and a one year high of $0.41.
Zomedica (NYSEAMERICAN:ZOM – Get Rating) last announced its earnings results on Wednesday, March 15th. The company reported ($0.01) EPS for the quarter. The firm had revenue of $6.16 million during the quarter, compared to the consensus estimate of $6.20 million. Zomedica had a negative return on equity of 7.31% and a negative net margin of 94.20%. On average, analysts predict that Zomedica Corp. will post -0.01 earnings per share for the current year.
Institutional Inflows and Outflows
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals.
- Get a free copy of the StockNews.com research report on Zomedica (ZOM)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.